Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) is expected to be announcing its earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $0.86 million for the quarter.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million for the quarter, compared to analysts' expectations of $1.40 million. On average, analysts expect Dianthus Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Dianthus Therapeutics Price Performance
NASDAQ DNTH traded down $0.62 during trading hours on Thursday, reaching $21.28. 259,714 shares of the company's stock traded hands, compared to its average volume of 227,231. Dianthus Therapeutics has a 52-week low of $18.13 and a 52-week high of $33.77. The firm has a market cap of $629.82 million, a PE ratio of -8.51 and a beta of 1.82. The firm has a 50-day simple moving average of $22.65 and a 200 day simple moving average of $24.94.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on DNTH. Wedbush reissued an "outperform" rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday. TD Cowen started coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They set a "buy" rating on the stock. Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Guggenheim reissued a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $52.14.
Check Out Our Latest Analysis on Dianthus Therapeutics
About Dianthus Therapeutics
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Read More
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
